Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer - 22/03/24

Abstract |
Deubiquitination, a post-translational modification regulated by deubiquitinases, is essential for cancer initiation and progression. Ubiquitin-specific proteases (USPs) are essential elements of the deubiquitinase family, and are overexpressed in gastric cancer (GC). Through the regulation of several signaling pathways, such as Wnt/β-Catenin and nuclear factor-κB signaling, and the promotion of the expression of deubiquitination- and stabilization-associated proteins, USPs promote the proliferation, metastasis, invasion, and epithelial-mesenchymal transition of GC. In addition, the expression of USPs is closely related to clinicopathological features, patient prognosis, and chemotherapy resistance. USPs therefore could be used as prognostic biomarkers. USP targeting small molecule inhibitors have demonstrated strong anticancer activity. However, they have not yet been tested in the clinic. This article provides an overview of the latest fundamental research on USPs in GC, aiming to enhance the understanding of how USPs contribute to GC progression, and identifying possible targets for GC treatment to improve patient survival.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | USPs that target ubiquitin proteins affect gastric cancer progression by regulating signaling pathways. |
• | USPs are closely linked to clinicopathological features and can be used as prognostic factors. |
• | Small molecule inhibitors targeting USPs have evident antitumor activity in vitro. |
Abbreviations : EMT, GC, HER, LSD1, MCL-1, MMP, PD-L1, PLK, PKM2, PRL-3, SDC2, SUZ12, TGF-β, USPs
Keywords : Gastric cancer, Ubiquitin-specific proteases, Deubiquitination, Inhibitors
Plan
Vol 173
Article 116323- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
